Brokerages Set Progyny, Inc. (NASDAQ:PGNY) Price Target at $33.25

Progyny, Inc. (NASDAQ:PGNY) has received a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $33.25.

PGNY has been the subject of several analyst reports. Leerink Partners set a $38.00 price objective on Progyny in a report on Wednesday, July 22nd. Canaccord Genuity Group increased their price target on Progyny from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Citizens Jmp raised their price target on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. KeyCorp boosted their price target on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Finally, Bank of America upped their price objective on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd.

Insider Activity

In other Progyny news, Director Cheryl Scott sold 7,439 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $26.39, for a total value of $196,315.21. Following the completion of the sale, the director owned 19,772 shares in the company, valued at $521,783.08. This trade represents a 27.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Allison Swartz sold 1,199 shares of Progyny stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total transaction of $29,998.98. Following the completion of the transaction, the executive vice president directly owned 83,316 shares of the company’s stock, valued at approximately $2,084,566.32. This trade represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 36,916 shares of company stock valued at $939,875. 9.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Progyny

Hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its position in Progyny by 53.3% during the second quarter. Versant Capital Management Inc now owns 4,330 shares of the company’s stock worth $125,000 after buying an additional 1,506 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of Progyny by 49.4% in the first quarter. Pacer Advisors Inc. now owns 435,558 shares of the company’s stock valued at $7,396,000 after purchasing an additional 144,073 shares during the last quarter. Segall Bryant & Hamill LLC raised its position in shares of Progyny by 68.4% in the first quarter. Segall Bryant & Hamill LLC now owns 82,198 shares of the company’s stock valued at $1,396,000 after purchasing an additional 33,380 shares during the period. Bank of America Corp DE raised its position in shares of Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock valued at $20,223,000 after purchasing an additional 511,609 shares during the period. Finally, South Dakota Investment Council lifted its stake in shares of Progyny by 20.0% during the 1st quarter. South Dakota Investment Council now owns 137,524 shares of the company’s stock worth $2,335,000 after buying an additional 22,900 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Trading Down 0.2%

Shares of PGNY opened at $31.48 on Friday. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of 40.88, a PEG ratio of 2.50 and a beta of 1.01. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The firm has a fifty day simple moving average of $28.82 and a 200 day simple moving average of $23.31.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. During the same period in the previous year, the business earned $0.17 EPS. The company’s revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts predict that Progyny will post 1.19 earnings per share for the current fiscal year.

Progyny declared that its Board of Directors has authorized a share buyback program on Tuesday, May 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.